Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 141 articles:
HTML format



Single Articles


    July 2022
  1. GIRI S, Ingawale S
    Use of restrictive iron transfusion strategy in inflammatory bowel disease: one size does not fit all.
    Eur J Gastroenterol Hepatol. 2022;34:807.
    PubMed    


  2. GROVA M, Crispino F, Maida M, Macaluso FS, et al
    Authors' reply to 'Use of restrictive iron transfusion strategy in IBD: one size does not fit all'.
    Eur J Gastroenterol Hepatol. 2022;34:808.
    PubMed    


    April 2022
  3. FERRANTE M, Schirbel A, Pierik MJ, Haas T, et al
    Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study.
    Eur J Gastroenterol Hepatol. 2022 Apr 8. pii: 00042737-990000000-00016.
    PubMed     Abstract available


  4. GOMOLLON F, Gisbert JP, Guerra I, Plaza R, et al
    Clinical characteristics and prognostic factors for Crohn's disease relapses using natural language processing and machine learning: a pilot study.
    Eur J Gastroenterol Hepatol. 2022;34:389-397.
    PubMed     Abstract available


  5. BODINI G, Demarzo MG, Djahandideh A, Ziola S, et al
    Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques.
    Eur J Gastroenterol Hepatol. 2022;34:382-388.
    PubMed     Abstract available


  6. HOWARD G, Weiner D, Bar-Or I, Levine A, et al
    Dual biologic therapy with Vedolizumab and Ustekinumab for refractory Crohn's disease in children.
    Eur J Gastroenterol Hepatol. 2022;34:372-374.
    PubMed     Abstract available


    March 2022
  7. SMITH RL, Taylor KM, Friedman AB, Gibson DJ, et al
    Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022 Mar 29. pii: 00042737-990000000-00008.
    PubMed     Abstract available


  8. CHUCK W, Shadbolt BF, Nordin F, Subramaniam K, et al
    BMI is important in predicting the loss of response in inflammatory bowel disease patients on tumour necrosis factor-alpha inhibitors.
    Eur J Gastroenterol Hepatol. 2022 Mar 29. pii: 00042737-990000000-00002.
    PubMed     Abstract available


  9. YOSHIDA A, Kimura K, Morizane T, Ueno F, et al
    Predictor of primary response to antitumor necrosis factor-alpha therapy for inflammatory bowel disease: a single-center observational study.
    Eur J Gastroenterol Hepatol. 2022 Mar 29. pii: 00042737-990000000-00007.
    PubMed     Abstract available


  10. LEI N, Kong P, Chen S, Wang Q, et al
    Upregulated NORAD is implicated in apoptosis, inflammation, and oxidative stress in ulcerative colitis through the nuclear factor-kappaappaB signaling.
    Eur J Gastroenterol Hepatol. 2022 Mar 29. pii: 00042737-990000000-00004.
    PubMed     Abstract available


  11. POO S, Sriranganathan D, Segal JP
    Network meta-analysis: efficacy of treatment for acute, chronic, and prevention of pouchitis in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2022 Mar 9. pii: 00042737-900000000-97083.
    PubMed     Abstract available


  12. DAWRA S, Manrai M, Kumar A, Kumar S, et al
    Hyperbaric oxygen therapy in inflammatory bowel disease: a systemic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2022;34:359-360.
    PubMed    


  13. TUN GSZ, Robinson K, Marshall L, Wright A, et al
    The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab.
    Eur J Gastroenterol Hepatol. 2022;34:295-301.
    PubMed     Abstract available


    February 2022
  14. FALLING CL, Stebbings S, David Baxter G, Siegel CA, et al
    Somatosensory assessments in patients with inflammatory bowel disease: a cross-sectional study examining pain processing pathways and the role of multiple patient factors.
    Eur J Gastroenterol Hepatol. 2022 Feb 14. pii: 00042737-900000000-97087.
    PubMed     Abstract available


    January 2022
  15. GROVA M, Crispino F, Maida M, Renna S, et al
    Effectiveness and safety of an on-demand ferric carboxymaltose infusion strategy in patients with inflammatory bowel disease: a real world experience.
    Eur J Gastroenterol Hepatol. 2022 Jan 31. pii: 00042737-900000000-97093.
    PubMed     Abstract available


  16. GIANNOS P, Triantafyllidis KK, Giannos G, Kechagias KS, et al
    SPP1 in infliximab resistant ulcerative colitis and associated colorectal cancer: an analysis of differentially expressed genes.
    Eur J Gastroenterol Hepatol. 2022 Jan 31. pii: 00042737-900000000-97092.
    PubMed     Abstract available


  17. KRUIS W, Leifeld L
    Response to: Malignancy associated to perianal Chrohn s fistula - a challenge for more clinical research.
    Eur J Gastroenterol Hepatol. 2022;34:9-10.
    PubMed    


  18. ADEGBOLA SO, Sarafian M, Sahnan K, Pechlivanis A, et al
    Lack of anti-TNF drugs levels in fistula tissue - a reason for nonresponse in Crohn's perianal fistulating disease?
    Eur J Gastroenterol Hepatol. 2022;34:18-26.
    PubMed     Abstract available


    December 2021
  19. THOMAS PWA, Smits LJT, Te Groen M, West RL, et al
    De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation.
    Eur J Gastroenterol Hepatol. 2021 Dec 30. pii: 00042737-900000000-97101.
    PubMed     Abstract available


  20. GUILLO L, Bonnaud G, Nahon S, Caron B, et al
    French experience with telemedicine in inflammatory bowel disease: a patients and physicians survey.
    Eur J Gastroenterol Hepatol. 2021 Dec 3. pii: 00042737-900000000-97115.
    PubMed     Abstract available


  21. GOODDAY SM, Travis S, Walsh A, Friend SH, et al
    Stress-related consequences of the coronavirus disease 2019 pandemic on symptoms of Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33:1511-1516.
    PubMed     Abstract available


  22. ADEGBOLA SO, Sarafian M, Sahnan K, Ding NS, et al
    Differences in amino acid and lipid metabolism distinguish Crohn's from idiopathic/cryptoglandular perianal fistulas by tissue metabonomic profiling and may offer clues to underlying pathogenesis.
    Eur J Gastroenterol Hepatol. 2021;33:1469-1479.
    PubMed     Abstract available


  23. SINGH AK, Kumar-M P, Sharma V
    Hyperbaric oxygen therapy for ulcerative colitis: conflicting evidence from randomized trials.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  24. TURSI A
    Performances of anti-TNFalpha antibodies as long-term maintenance therapy for ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  25. MOURAD FH, Leong RW, Kariyawasam VC
    Early thiopurine maintenance and reduced colectomy rate in ulcerative colitis: fact or fiction?
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  26. NG A
    Mind the lipids: hyperlipidaemia resultant from JAK inhibitor use in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  27. NG A
    Early thiopurine maintenance and reduced colectomy rate in ulcerative colitis: fact or fiction?
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  28. NG A
    The efficacy of tumour necrosis factor-alpha antagonists in maintenance therapy for ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  29. GARRIDO I, Santos AL, Lopes J, Lopes S, et al
    "Hepatotoxicity in inflammatory bowel disease: mesalazine, the forgotten drug".
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  30. DING NS, Lee T, Bettenworth D, Cleynen I, et al
    Assessing aCCess to Investigations in Inflammatory Bowel Disease (ACCID): results from an international survey.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  31. INNOCENTI T, Roselli J, Lynch EN, Apolito P, et al
    Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  32. VIOLA A, Muscianisi M, Voti RL, Costantino G, et al
    Predictors of Covid-19 vaccination acceptance in IBD patients: a prospective study.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  33. HILARY K, Carthage M, Jawad R, Karen B, et al
    Lost in words? The readability of medication information sheets in commonly used medication in inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  34. NG A
    Histological subtypes of perianal fistula-associated malignancies in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  35. SILVA MENDES S, Ferreira P, Antunes P, Goncalves M, et al
    Validation of the IBD-Disk in a Portuguese cohort.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  36. LI X, Wang Y, Ge T, Xiao Y, et al
    Henoch-Schonlein purpura associated with infliximab therapy for pediatric Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  37. HANZEL J, Kozelj M, Spes Hlastec A, Kurent T, et al
    Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  38. TEN BOKKEL HUININK S, Biemans V, Duijvestein M, Pierik M, et al
    Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  39. PIAZZOLLA M, Marmo R, Terracciano F, Perri F, et al
    Asymptomatic retention of fragmented small bowel capsule endoscopy retrieved by retrograde double-balloon enteroscopy in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  40. SALVATORI S, Marafini I, Monteleone G
    Paradoxical hidradenitis suppurativa in Crohn's disease patients receiving infliximab: a case report and review of literature.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  41. LI T, Gao L, Cao L, Guo Z, et al
    Changes in disease behaviour and location and factor analysis in patients with Crohn's disease undergoing repeated-resections.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  42. CROCETTI E, Bergamaschi W, Russo AG
    Population-based incidence and prevalence of inflammatory bowel diseases in Milan (Northern Italy), and estimates for Italy.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  43. WALSHE M, Borowski K, Boland K, Rho S, et al
    Ustekinumab induction concentrations are associated with clinical and biochemical outcomes at week 12 of treatment in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


    November 2021
  44. YAO J, Gao R, Luo M, Li D, et al
    Long noncoding RNA KIF9-AS1 promotes cell apoptosis by targeting the microRNA-148a-3p/suppressor of cytokine signaling axis in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Nov 8. pii: 00042737-900000000-97127.
    PubMed     Abstract available


  45. TURSI A, Florio T, Tiano M
    Successful treatment of concomitant Crohn's disease and psoriasis with risankizumab.
    Eur J Gastroenterol Hepatol. 2021;33:1462-1464.
    PubMed    


  46. PUTIGNANI L, Oliva S, Isoldi S, Del Chierico F, et al
    Fecal and mucosal microbiota profiling in pediatric inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2021;33:1376-1386.
    PubMed     Abstract available


    October 2021
  47. SHAMSEYA AM, Hussein WM, Elnely DA, Adel F, et al
    Serum matrix metalloproteinase-9 concentration as a marker of disease activity in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Oct 20. pii: 00042737-900000000-97135.
    PubMed     Abstract available


  48. VELAYOS JIMENEZ B, Del Olmo Martinez L, Macho Conesa A, Fernandez Salazar L, et al
    Should the birth month be considered as one of the possible environmental risk factors in the pathogenesis of inflammatory bowel disease?
    Eur J Gastroenterol Hepatol. 2021;33:1332.
    PubMed    


  49. GREENER T, Boland K, Milgrom R, Ben-Bassat O, et al
    Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn's disease patients.
    Eur J Gastroenterol Hepatol. 2021;33:1274-1279.
    PubMed     Abstract available


    August 2021
  50. BAMIAS G, Kokkotis G, Christidou A, Christodoulou DK, et al
    The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD.
    Eur J Gastroenterol Hepatol. 2021 Aug 16. pii: 00042737-900000000-97160.
    PubMed     Abstract available


  51. KARIMI N, Sechi AJ, Harb M, Sawyer E, et al
    The effect of a nurse-led advice line and virtual clinic on inflammatory bowel disease service delivery: an Australian study.
    Eur J Gastroenterol Hepatol. 2021 Aug 16. pii: 00042737-900000000-97158.
    PubMed     Abstract available


  52. CAPRIOLI F, Daperno M, Bravata I, Brigido A, et al
    Who are the patients with Crohn's disease unsuitable to receive an anti-TNFalpha therapy? Results from a survey of Italian physicians and literature review.
    Eur J Gastroenterol Hepatol. 2021;33:1082-1090.
    PubMed     Abstract available


  53. GONG W, Guo K, Zheng T, Xie H, et al
    JINLING (Judicious INdex of Luminal INflammation Grade) score, an effective indicator to assess inflammation severity in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33:1049-1054.
    PubMed     Abstract available


    July 2021
  54. SMITH RL, Taylor KM, Friedman AB, Su HY, et al
    Interrater reliability of the assessment of disease activity by gastrointestinal ultrasound in a prospective cohort of patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Jul 30. pii: 00042737-900000000-97173.
    PubMed     Abstract available


  55. GONZALEZ-PARTIDA I, Martinez-Lozano H, Gonzalez-Lois C, Peligros I, et al
    Histological inflammatory activity can predict endoscopic relapse in patients with ulcerative colitis who have achieved mucosal healing.
    Eur J Gastroenterol Hepatol. 2021 Jul 30. pii: 00042737-900000000-97168.
    PubMed     Abstract available


  56. ORFANOUDAKI E, Drygiannakis I, Theodoraki E, Foteinogiannopoulou K, et al
    Real-life utility and diagnostic accuracy of a home-performed fecal calprotectin test to predict endoscopic activity in patients with inflammatory bowel disease under maintenance treatment with adalimumab.
    Eur J Gastroenterol Hepatol. 2021 Jul 19. pii: 00042737-900000000-97178.
    PubMed     Abstract available


  57. CORTEGOSO VALDIVIA P, Elosua A, Houdeville C, Pennazio M, et al
    Clinical feasibility of panintestinal (or panenteric) capsule endoscopy: a systematic review.
    Eur J Gastroenterol Hepatol. 2021;33:949-955.
    PubMed     Abstract available


  58. NERI B, Scarozza P, Giannarelli D, Sena G, et al
    Efficacy and tolerability of very low-volume bowel preparation in patients with inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2021;33:977-982.
    PubMed     Abstract available


  59. LIVNE M, Amitai MM, Klang E, Ben Horin S, et al
    Qualitative sonographic assessment of transmural ileal inflammation in Crohn's disease: a comparison with MRI activity score.
    Eur J Gastroenterol Hepatol. 2021;33:961-966.
    PubMed     Abstract available


    June 2021
  60. RICHTER V, Bermont A, Cohen DL, Broide E, et al
    Effect of inflammatory bowel disease and related medications on COVID-19 incidence, disease severity, and outcome: the Israeli experience.
    Eur J Gastroenterol Hepatol. 2021 Jun 29. pii: 00042737-900000000-97186.
    PubMed     Abstract available


  61. ATTAUABI M, Vind I, Pedersen G, Bendtsen F, et al
    Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease - a real-world two-center cohort study.
    Eur J Gastroenterol Hepatol. 2021 Jun 7. pii: 00042737-900000000-97194.
    PubMed     Abstract available


  62. LLAO J, Masnou H, Romero C, Bargallo A, et al
    Noninvasive assessment of liver fibrosis in Crohn's disease patients exposed to methotrexate.
    Eur J Gastroenterol Hepatol. 2021;33:794-798.
    PubMed     Abstract available


    May 2021
  63. RIZOS ED, Antonogiannaki EM, Chatzidakis A, Kallieri M, et al
    Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021 May 31. pii: 00042737-900000000-97199.
    PubMed     Abstract available


  64. GATOPOULOU A, Christodoulou DK, Katsanos KH, Bakos D, et al
    Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Gree
    Eur J Gastroenterol Hepatol. 2021 May 21. pii: 00042737-900000000-97217.
    PubMed     Abstract available


  65. VOHRA I, Attar B, Haghbin H, Mutneja H, et al
    Incidence and risk factors for 30-day readmission in ulcerative colitis: nationwide analysis in biologic era.
    Eur J Gastroenterol Hepatol. 2021 May 21. pii: 00042737-900000000-97210.
    PubMed     Abstract available


  66. ANGELINO G, Cifaldi C, Zangari P, Di Cesare S, et al
    Gastric cancer, inflammatory bowel disease and polyautoimmunity in a 17-year-old boy: CTLA-4 deficiency successfully treated with Abatacept.
    Eur J Gastroenterol Hepatol. 2021 May 21. pii: 00042737-900000000-97208.
    PubMed     Abstract available


  67. VAN GENNEP S, Gielen ME, Rietdijk ST, de Boer NKH, et al
    Work productivity loss is determined by fatigue and reduced quality of life in employed inflammatory bowel disease patients: a prospective multicentre cohort study.
    Eur J Gastroenterol Hepatol. 2021 May 3. doi: 10.1097/MEG.0000000000002178.
    PubMed     Abstract available


  68. VIGLIO A, Lenti MV, Vanoli A, Di Sabatino A, et al
    Rectal neuroendocrine cell proliferation in a patient with ulcerative colitis treated with adalimumab.
    Eur J Gastroenterol Hepatol. 2021;33:766-768.
    PubMed    


  69. TURSI A, Mocci G, Lorenzetti R, Allegretta L, et al
    Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
    Eur J Gastroenterol Hepatol. 2021;33:670-679.
    PubMed     Abstract available


  70. FREITAS M, Curdia Goncalves T, Boal Carvalho P, Dias de Castro F, et al
    From terminal ileitis to Crohn's disease: how capsule endoscopy is crucial to diagnosis.
    Eur J Gastroenterol Hepatol. 2021;33:631-638.
    PubMed     Abstract available


    April 2021
  71. SINGH AK, Jha DK, Jena A, Kumar-M P, et al
    Hyperbaric oxygen therapy in inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2021 Apr 19. doi: 10.1097/MEG.0000000000002164.
    PubMed     Abstract available


  72. CORREIA JP, Ponte AI, Silva JC, Gomes AC, et al
    Mesalazine-induced acute pancreatitis: a rare adverse reaction but with important therapeutic implications in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021;33:595.
    PubMed    


  73. GONELLA F, Massucco P, Daperno M, Mineccia M, et al
    Ulcerative enteritis. How the extension of ulcerative colitis to small bowel may jeopardize postcolectomy course: a case report and literature review.
    Eur J Gastroenterol Hepatol. 2021;33:589-594.
    PubMed     Abstract available


  74. GOMES C, Pinho R, Ponte A, Silva JC, et al
    Patient's perspective on the implementation of measures to contain the SARS-CoV-2 pandemic in a Portuguese Gastroenterology Department.
    Eur J Gastroenterol Hepatol. 2021;33:527-532.
    PubMed     Abstract available


  75. TAMILARASAN AG, Krishnananthan T
    Faecal microbiota transplantation: what's beyond Clostridium difficile infection?
    Eur J Gastroenterol Hepatol. 2021;33:487-494.
    PubMed     Abstract available


    March 2021
  76. CROOKS B, Misra R, Arebi N, Kok K, et al
    The dietary practices and beliefs of people living with older-onset inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Mar 18. pii: 00042737-900000000-97269.
    PubMed     Abstract available


  77. FERNANDES SR, Serrazina J, Rodrigues IC, Bernardo S, et al
    Proactive therapeutic drug monitoring is more effective than conventional management in inducing fecal calprotectin remission in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Mar 12. pii: 00042737-900000000-97288.
    PubMed     Abstract available


  78. KARIYAWASAM VC, Mourad FH, Mitrev N, Paramsothy S, et al
    Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021 Mar 12. pii: 00042737-900000000-97273.
    PubMed     Abstract available


  79. SCHARRER S, Kutschera M, Weseslindtner L, Primas C, et al
    Humoral response to COVID-19 infection in immunosuppressed patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021;33:443-447.
    PubMed     Abstract available


  80. CANCADO GGL, Nardelli MJ, Gouthier MAD
    Adalimumab-induced leukocytoclastic vasculitis in a Crohn's disease patient.
    Eur J Gastroenterol Hepatol. 2021;33:453.
    PubMed    


  81. SHARMA V, Verma S, Kumar-M P, Mandavdhare HS, et al
    Serial measurements of faecal calprotectin may discriminate intestinal tuberculosis and Crohn's disease in patients started on antitubercular therapy.
    Eur J Gastroenterol Hepatol. 2021;33:334-338.
    PubMed     Abstract available


    February 2021
  82. KYRIAKOS N, Papaefthymiou A, Giakoumis M, Galanopoulos M, et al
    Prevalence of inflammatory bowel disease in young Greek Army male recruits from 2006 to 2018: a 13-year retrospective study from a tertiary center.
    Eur J Gastroenterol Hepatol. 2021 Feb 26. pii: 00042737-900000000-97290.
    PubMed     Abstract available


  83. LOVERO R, Losurdo G, La Fortezza RF, Terracciano F, et al
    Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021;32:201-207.
    PubMed     Abstract available


  84. MANTAKA A, Tsoukali E, Fragaki M, Karmiris K, et al
    Reply to the letter to the Editor: 'The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease'.
    Eur J Gastroenterol Hepatol. 2021;32:300-302.
    PubMed    


    January 2021
  85. KOUMAKI D, Machaira A, Katoulis AC, Bitados P, et al
    Mucocutaneous manifestations in patients with inflammatory bowel disease: a decade study from a Greek cohort.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97312.
    PubMed     Abstract available


  86. UNAL NG, Oruc N, Tomey O, Omer Ozutemiz A, et al
    Malnutrition and sarcopenia are prevalent among inflammatory bowel disease patients with clinical remission.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97311.
    PubMed     Abstract available


  87. MAGRI S, Chessa L, Demurtas M, Cabras F, et al
    Review article: safety of new biologic agents for inflammatory bowel disease in the liver.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97310.
    PubMed     Abstract available


  88. STRAATMIJER T, van Gennep S, Duijvestein M, Ponsioen CIJ, et al
    Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
    PubMed     Abstract available


  89. FIGUEREDO CM, Nunes JGR, Mello-Neto JM, Carvalho AT, et al
    Higher salivary expression of S100A12 in patients with ulcerative colitis and chronic periodontitis.
    Eur J Gastroenterol Hepatol. 2021;33:116-117.
    PubMed    


    November 2020
  90. WEISLINGER L, Guillo L, D'Amico F, Danese S, et al
    Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002008.
    PubMed     Abstract available


  91. LYUTAKOV I, Lozanov V, Sugareva P, Valkov H, et al
    Serum 7-alfa-hydroxy-4-cholesten-3-one and fibroblast growth factor-19 as biomarkers diagnosing bile acid malabsorption in microscopic colitis and inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020 Nov 10. doi: 10.1097/MEG.0000000000001925.
    PubMed     Abstract available


  92. LYU L, Chen D, Yu M, Yang Y, et al
    The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020;32:1480-1481.
    PubMed    


    October 2020
  93. GILISSEN LPL, Tajzai R, Romberg M, Pierik M, et al
    The prevalence of nodular regenerative hyperplasia of the liver in long-term thiopurine-treated inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2020 Oct 29. doi: 10.1097/MEG.0000000000001980.
    PubMed     Abstract available


  94. ROMEO S, Neri B, Mossa M, Calabrese E, et al
    Finger clubbing in inflammatory bowel disease: association with upper small bowel lesions and need of surgery in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2020 Oct 29. doi: 10.1097/MEG.0000000000001966.
    PubMed     Abstract available


  95. KJAERGAARD S, Jensen TSR, Feddersen UR, Bindslev N, et al
    Decreased number of colonic tuft cells in quiescent ulcerative colitis patients.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001959.
    PubMed     Abstract available


  96. MOOSVI Z, Duong J, Bechtold ML, Nguyen DL, et al
    Systematic review and meta-analysis: risks of postoperative complications with preoperative use of anti-tumor necrosis factor-alpha biologics in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001944.
    PubMed     Abstract available


  97. BHAMBHVANI HP, Zamora A
    Deep learning enabled classification of Mayo endoscopic subscore in patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001952.
    PubMed     Abstract available


    September 2020
  98. LOPETUSO LR, Corbi M, Scaldaferri F, Petito V, et al
    Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF-a treatment.
    Eur J Gastroenterol Hepatol. 2020 Sep 23. doi: 10.1097/MEG.0000000000001933.
    PubMed     Abstract available


  99. VELLOPOULOU K, Stefanou G, Tzanetakos C, Boubouchairopoulou N, et al
    Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece.
    Eur J Gastroenterol Hepatol. 2020 Sep 23. doi: 10.1097/MEG.0000000000001916.
    PubMed     Abstract available


  100. MESONERO F, Julia B, Saldana R, Savini C, et al
    Self-medication with oral corticosteroids reported by patients with ulcerative colitis: characteristics, reasons and patients' behaviors.
    Eur J Gastroenterol Hepatol. 2020 Sep 17. doi: 10.1097/MEG.0000000000001931.
    PubMed     Abstract available


  101. HORESH N, Mansour A, Simon D, Edden Y, et al
    Postoperative outcomes following inguinal hernia repair in inflammatory bowel disease patients compared to matched controls.
    Eur J Gastroenterol Hepatol. 2020 Sep 17. doi: 10.1097/MEG.0000000000001936.
    PubMed     Abstract available


  102. CROOKS B, McLaughlin J, Matsuoka K, Kobayashi T, et al
    The dietary practices and beliefs of people living with inactive ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2020 Sep 17. doi: 10.1097/MEG.0000000000001911.
    PubMed     Abstract available


  103. BISCAGLIA G, Piazzolla M, Cocomazzi F, Melchionda G, et al
    Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab.
    Eur J Gastroenterol Hepatol. 2020 Sep 15. doi: 10.1097/MEG.0000000000001919.
    PubMed     Abstract available


  104. SBEIT W, Kadah A, Mahamid M, Karayanni H, et al
    Oral manifestations of inflammatory bowel disease: the neglected piece of the puzzle.
    Eur J Gastroenterol Hepatol. 2020 Sep 10. doi: 10.1097/MEG.0000000000001918.
    PubMed     Abstract available


  105. MANTAKA A, Tsoukali E, Fragkaki M, Karmiris K, et al
    Is there any role of renin-angiotensin system inhibitors in modulating inflammatory bowel disease outcome?
    Eur J Gastroenterol Hepatol. 2020 Sep 9. doi: 10.1097/MEG.0000000000001912.
    PubMed     Abstract available


  106. NIGAM GB, Bhandare AP, Antoniou GA, Limdi JK, et al
    Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy.
    Eur J Gastroenterol Hepatol. 2020 Sep 2. doi: 10.1097/MEG.0000000000001917.
    PubMed     Abstract available


    August 2020
  107. STEFANOVIC S, Detrez I, Compernolle G, Brouwers E, et al
    Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001843.
    PubMed     Abstract available


  108. WALJEE AK, Noureldin M, Berinstein JA, Cohen-Mekelburg SA, et al
    Mapping the relationships between inflammatory bowel disease and comorbid diagnoses to identify disease associations.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001869.
    PubMed     Abstract available


  109. CASELLAS F, Guinard Vicens D, Garcia-Lopez S, Gonzalez-Lama Y, et al
    Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001885.
    PubMed     Abstract available


  110. SRIVASTAVA A, Sathiyasekharan M, Jagadisan B, Bolia R, et al
    Paediatric inflammatory bowel disease in India: a prospective multicentre study.
    Eur J Gastroenterol Hepatol. 2020 Aug 10. doi: 10.1097/MEG.0000000000001859.
    PubMed     Abstract available


  111. SANTOS JDM, Pena-Sanchez JN, Fowler SA
    Patients' perspectives on medication for inflammatory bowel disease: a mixed-method systematic review.
    Eur J Gastroenterol Hepatol. 2020 Aug 7. doi: 10.1097/MEG.0000000000001861.
    PubMed     Abstract available


    June 2020
  112. ALAMDARI-PALANGI V, Vahedi F, Shabaninejad Z, Dokeneheifard S, et al
    microRNA in inflammatory bowel disease at a glance.
    Eur J Gastroenterol Hepatol. 2020 Jun 16. doi: 10.1097/MEG.0000000000001815.
    PubMed     Abstract available


  113. WIDBOM L, Ekblom K, Karling P, Hultdin J, et al
    Patients developing inflammatory bowel disease have iron deficiency and lower plasma ferritin years before diagnosis: a nested case-control study.
    Eur J Gastroenterol Hepatol. 2020 Jun 11. doi: 10.1097/MEG.0000000000001816.
    PubMed     Abstract available


  114. DESAI M, Knight K, Gray JM, Nguyen V, et al
    Low glutamate dehydrogenase levels are associated with colonization in Clostridium difficile PCR-only positive patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020 Jun 8. doi: 10.1097/MEG.0000000000001762.
    PubMed     Abstract available


  115. BASARANOGLU M, Kapsigay M, Kunduz E
    Increased neuroendocrine tumours, but small colorectal cancer incidence in patients with inflammatory bowel disease treated by mesalazine.
    Eur J Gastroenterol Hepatol. 2020;32:763.
    PubMed    


    May 2020
  116. KOURKOULIS P, Michalopoulos G, Katifelis H, Giannopoulou I, et al
    Leucine-rich alpha-2 glycoprotein 1, high mobility group box 1, matrix metalloproteinase 3 and annexin A1 as biomarkers of ulcerative colitis endoscopic and histological activity.
    Eur J Gastroenterol Hepatol. 2020 May 29. doi: 10.1097/MEG.0000000000001783.
    PubMed     Abstract available


  117. CHAN W, Kariyawasam VC, Kim S, Pudipeddi AV, et al
    Gastroenterologists' preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis: an international survey.
    Eur J Gastroenterol Hepatol. 2020 May 22. doi: 10.1097/MEG.0000000000001768.
    PubMed     Abstract available


  118. OZKAN E, Basaranoglu M
    Recurrent 'gloves and socks' distribution with bullous eruptions after adalimumab and infliximab treatment in a patient with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2020;32:666-667.
    PubMed    


    April 2020
  119. LI Q, Zhang T, Ding X, Xiang L, et al
    Enhancing patient adherence to fecal microbiota transplantation maintains the long-term clinical effects in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2020 Apr 10. doi: 10.1097/MEG.0000000000001725.
    PubMed     Abstract available


  120. BARDASI G, Romagnoli A, Foschini MP, Mantovani A, et al
    Pyostomatitis vegetans in a pediatric patient with ulcerative colitis: case report of a rare pediatric inflammatory bowel disease extraintestinal manifestation and review of the literature.
    Eur J Gastroenterol Hepatol. 2020 Apr 10. doi: 10.1097/MEG.0000000000001723.
    PubMed     Abstract available


  121. BERTANI L, Mumolo MG, Tapete G, Albano E, et al
    Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment.
    Eur J Gastroenterol Hepatol. 2020 Apr 8. doi: 10.1097/MEG.0000000000001731.
    PubMed     Abstract available


  122. HANAEI S, Sanati G, Sadr M, Salmanroghani R, et al
    DNA methylation of SOCS3 in intestinal biopsy and peripheral blood samples of Iranian patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2020;32:540-541.
    PubMed    


  123. GUNEY M, Basaranoglu M
    A patient with Crohn's disease during remission by biological agent treatment developed active pulmonary tuberculosis and determining the eating habits.
    Eur J Gastroenterol Hepatol. 2020;32:541-542.
    PubMed    


    March 2020
  124. LI X, Sun L, Chen L, Xu Y, et al
    Upregulation of microRNA-219-5p relieves ulcerative colitis through balancing the differentiation of Treg/Th17 cells.
    Eur J Gastroenterol Hepatol. 2020 Mar 13. doi: 10.1097/MEG.0000000000001712.
    PubMed     Abstract available


    February 2020
  125. PHILLIPS J, Preskey R, Penfold C, Gordon F, et al
    Liver steatosis is a risk factor for hepatotoxicity in inflammatory bowel disease patients treated with azathioprine.
    Eur J Gastroenterol Hepatol. 2020 Feb 21. doi: 10.1097/MEG.0000000000001683.
    PubMed     Abstract available


  126. KARAIVAZOGLOU K, Konstantakis C, Tourkochristou E, Assimakopoulos SF, et al
    Non-alcoholic fatty liver disease in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2020 Feb 8. doi: 10.1097/MEG.0000000000001679.
    PubMed     Abstract available


  127. CHARILAOU P
    Walking on thin ice: considering the fragility index in randomized control trials.
    Eur J Gastroenterol Hepatol. 2020;32:139.
    PubMed    


  128. EMAN AS, Shaji S
    Is MRI healing the target in treating perianal fistulizing Crohn's disease?
    Eur J Gastroenterol Hepatol. 2020;32:137-138.
    PubMed    


    January 2020
  129. MANTAKA A, Tsoukali E, Fragkaki M, Karmiris K, et al
    The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020 Jan 8. doi: 10.1097/MEG.0000000000001674.
    PubMed     Abstract available


    December 2019
  130. ALGETHMI W, Baumann C, Alnajjar W, Sroji A, et al
    Environmental exposures and the risk of inflammatory bowel disease: a case-control study from Saudi Arabia.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001619.
    PubMed     Abstract available


  131. KUMAR A, Lukin DJ
    Incident heart failure is a predictor of adverse outcomes in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001648.
    PubMed     Abstract available


  132. NERI B, Stingone C, Romeo S, Sena G, et al
    Inflammatory bowel disease versus Chlamydia trachomatis infection: a case report and revision of the literature.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001605.
    PubMed     Abstract available


  133. SWEENEY L, Moss-Morris R, Czuber-Dochan W, Murrells T, et al
    Developing a better biopsychosocial understanding of pain in inflammatory bowel disease: a cross-sectional study.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001615.
    PubMed     Abstract available


  134. SCHOEPFER A, Vavricka SR, Brungger B, Blozik E, et al
    Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland.
    Eur J Gastroenterol Hepatol. 2019 Dec 9. doi: 10.1097/MEG.0000000000001616.
    PubMed     Abstract available


    November 2019
  135. KAWAKAMI A, Choong LM, Tanaka M, Kunisaki R, et al
    Validation of the English version of the difficulty of life scale for patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2019 Nov 7. doi: 10.1097/MEG.0000000000001595.
    PubMed     Abstract available


  136. VIOLA A, Monterubbianesi R, Scalisi G, Furfaro F, et al
    Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study.
    Eur J Gastroenterol Hepatol. 2019;31:1361-1369.
    PubMed     Abstract available


  137. NAFTALI T, Bar-Lev Schleider L, Sklerovsky Benjaminov F, Lish I, et al
    Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects.
    Eur J Gastroenterol Hepatol. 2019;31:1376-1381.
    PubMed     Abstract available


    October 2019
  138. LANGHORST J, Koch AK, Voiss P, Dobos GJ, et al
    Distinct patterns of short-chain fatty acids during flare in patients with ulcerative colitis under treatment with mesalamine or a herbal combination of myrrh, chamomile flowers, and coffee charcoal: secondary analysis of a randomized controlled trial
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001582.
    PubMed     Abstract available


  139. KIM S, Park S, Kang Y, Koh H, et al
    Combining faecal calprotectin and sigmoidoscopy can predict mucosal healing in paediatric ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2019 Oct 22. doi: 10.1097/MEG.0000000000001550.
    PubMed     Abstract available


  140. QUIROZ-CRUZ S, Posada-Reyes B, Alatorre-Garcia T, Del Real-Calzada CM, et al
    Genetic polymorphisms present in IL10, IL23R, NOD2, and ATG16L1 associated with susceptibility to inflammatory bowel disease in Mexican population.
    Eur J Gastroenterol Hepatol. 2019 Oct 22. doi: 10.1097/MEG.0000000000001540.
    PubMed     Abstract available


    September 2019
  141. SCHOENEFUSS F, Hoffmann P
    Serum gamma-globulin and albumin concentrations predict secondary loss of response to anti-TNFalpha in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2019 Sep 16. doi: 10.1097/MEG.0000000000001493.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: